BIM Stock Overview
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
Price History & Performance
|Historical stock prices|
|Current Share Price||€88.52|
|52 Week High||€133.20|
|52 Week Low||€80.70|
|1 Month Change||-6.47%|
|3 Month Change||-12.40%|
|1 Year Change||-6.27%|
|3 Year Change||20.11%|
|5 Year Change||45.91%|
|Change since IPO||785.20%|
Recent News & Updates
Shareholders Would Enjoy A Repeat Of bioMérieux's (EPA:BIM) Recent Growth In Returns
If you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
bioMérieux (EPA:BIM) Is Paying Out A Larger Dividend Than Last Year
bioMérieux S.A.'s ( EPA:BIM ) dividend will be increasing to €0.85 on 8th of June. Despite this raise, the dividend...
|BIM||FR Medical Equipment||FR Market|
Return vs Industry: BIM exceeded the French Medical Equipment industry which returned -8.5% over the past year.
Return vs Market: BIM underperformed the French Market which returned -4.2% over the past year.
|BIM Average Weekly Movement||6.3%|
|Medical Equipment Industry Average Movement||6.7%|
|Market Average Movement||6.2%|
|10% most volatile stocks in FR Market||10.5%|
|10% least volatile stocks in FR Market||3.6%|
Stable Share Price: BIM is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: BIM's weekly volatility (6%) has been stable over the past year.
About the Company
bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories.
bioMérieux Fundamentals Summary
|BIM fundamental statistics|
Is BIM overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BIM income statement (TTM)|
|Cost of Revenue||€1.41b|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Aug 31, 2022
|Earnings per share (EPS)||5.08|
|Net Profit Margin||17.80%|
How did BIM perform over the long term?See historical performance and comparison
1.0%Current Dividend Yield
Does BIM pay a reliable dividends?See BIM dividend history and benchmarks
|bioMérieux dividend dates|
|Ex Dividend Date||Jun 06 2022|
|Dividend Pay Date||Jun 08 2022|
|Days until Ex dividend||21 days|
|Days until Dividend pay date||23 days|
Does BIM pay a reliable dividends?See BIM dividend history and benchmarks
Is bioMérieux undervalued compared to its fair value and its price relative to the market?
Valuation Score 2/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BIM (€88.52) is trading below our estimate of fair value (€189.88)
Significantly Below Fair Value: BIM is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: BIM is poor value based on its PE Ratio (17.4x) compared to the French Medical Equipment industry average (13.4x).
PE vs Market: BIM is poor value based on its PE Ratio (17.4x) compared to the French market (16.4x).
Price to Earnings Growth Ratio
PEG Ratio: BIM's earnings are forecast to decline next year, so we can't calculate its PEG ratio.
Price to Book Ratio
PB vs Industry: BIM is overvalued based on its PB Ratio (3.4x) compared to the FR Medical Equipment industry average (2.2x).
How is bioMérieux forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIM's earnings are forecast to decline over the next 3 years (-7.5% per year).
Earnings vs Market: BIM's earnings are forecast to decline over the next 3 years (-7.5% per year).
High Growth Earnings: BIM's earnings are forecast to decline over the next 3 years.
Revenue vs Market: BIM's revenue (2.7% per year) is forecast to grow slower than the French market (5.7% per year).
High Growth Revenue: BIM's revenue (2.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BIM's Return on Equity is forecast to be low in 3 years time (12.3%).
How has bioMérieux performed over the past 5 years?
Past Performance Score5/6
Past Performance Score 5/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BIM has high quality earnings.
Growing Profit Margin: BIM's current net profit margins (17.8%) are higher than last year (13%).
Past Earnings Growth Analysis
Earnings Trend: BIM's earnings have grown significantly by 22.3% per year over the past 5 years.
Accelerating Growth: BIM's earnings growth over the past year (48.6%) exceeds its 5-year average (22.3% per year).
Earnings vs Industry: BIM earnings growth over the past year (48.6%) exceeded the Medical Equipment industry 29.7%.
Return on Equity
High ROE: BIM's Return on Equity (18.8%) is considered low.
How is bioMérieux's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: BIM's short term assets (€2.2B) exceed its short term liabilities (€955.8M).
Long Term Liabilities: BIM's short term assets (€2.2B) exceed its long term liabilities (€486.5M).
Debt to Equity History and Analysis
Debt Level: BIM has more cash than its total debt.
Reducing Debt: BIM's debt to equity ratio has reduced from 25.2% to 10.7% over the past 5 years.
Debt Coverage: BIM's debt is well covered by operating cash flow (238.5%).
Interest Coverage: BIM's interest payments on its debt are well covered by EBIT (108.2x coverage).
What is bioMérieux current dividend yield, its reliability and sustainability?
Dividend Score 3/6
Future Dividend Coverage
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
Notable Dividend: BIM's dividend (0.96%) isn’t notable compared to the bottom 25% of dividend payers in the French market (1.71%).
High Dividend: BIM's dividend (0.96%) is low compared to the top 25% of dividend payers in the French market (5.05%).
Stability and Growth of Payments
Stable Dividend: BIM's dividend payments have been volatile in the past 10 years.
Growing Dividend: BIM's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its low payout ratio (16.7%), BIM's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (19.3%), BIM's dividend payments are well covered by cash flows.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Alexandre Merieux (47 yo)
Mr. Alexandre Merieux serves as the Chairman and Chief Executive Officer of bioMérieux, Inc. Mr. Merieux serves as the President and Chairman of the Management Board of Merieux Développement SAS. He joined...
CEO Compensation Analysis
Compensation vs Market: Alexandre's total compensation ($USD1.55M) is below average for companies of similar size in the French market ($USD3.61M).
Compensation vs Earnings: Alexandre's compensation has increased by more than 20% in the past year.
Experienced Management: BIM's management team is considered experienced (4.2 years average tenure).
Experienced Board: BIM's board of directors are considered experienced (9 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
bioMérieux S.A.'s employee growth, exchange listings and data sources
- Name: bioMérieux S.A.
- Ticker: BIM
- Exchange: ENXTPA
- Founded: 1963
- Industry: Health Care Equipment
- Sector: Healthcare
- Implied Market Cap: €10.467b
- Shares outstanding: 118.25m
- Website: https://www.biomerieux.com
Number of Employees
- bioMérieux S.A.
- 376 Chemin De l’Orme
- Marcy l'Étoile
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/15 00:00|
|End of Day Share Price||2022/05/13 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.